pf-06647020
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02222922)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Inactive tyrosine-protein kinase 7INHIBITOR
PTK7 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin F
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989983 ↗
Also known as
- pf-06647020
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04189614 | Phase 1 | Dec 16, 2019 | AbbVie, Pfizer |
| NCT02222922 | Phase 1 | Oct 1, 2014 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1